‘Global Interventional Cardiology Market Worth $13,920m In 2021’ Says Visiongain Report

28 August 2018
Pharma

Visiongain’s new report Global Interventional Cardiology Market 2017-2027: Percutaneous Coronary Intervention (PCI), Transcatheter Aortic Valve Implantation (TAVI), Transcatheter Mitral Valve Implantation (TMVR) indicates that the global interventional cardiology market will see $13,920m in spending in 2021.

The global interventional cardiology market is expected to grow at a CAGR of 11.1% in the first half of the forecast period and CAGR of 16.9% in the second half of the forecast period. The market is expected to grow at a CAGR of 15.0% from 2017 to 2027. The market is estimated at $13,920m in 2021 and $35,537m in 2027.

The lead analyst of the report said: “The Interventional Cardiology market is anticipated to witness a robust growth during the years of forecast owing to the growing awareness of existing technologies, launch of new innovative products and rapid adoption of these emerging technologies in developed countries such as US and Europe. Moreover, we anticipate more companies entering this market during the forecast period while; the existing players would try to fortify their global position through geographical expansion by setting up their operations in emerging economies such as China, India, Brazil, Russia and Middle East.
The growing prevalence of coronary heart diseases, aortic stenosis and mitral valve stenosis have triggered the demand for more innovative and less invasive. Hence, demand for interventional cardiac procedures is expected to drive the growth of interventional cardiology devices market. The TAVR and TMVR devices are expected to have high growth rate in the coming years. Visiongain also expects the bioresorbable stents market to witness a robust growth during the forecast period. However; premium pricing of these products may hinder the growth of the market especially in countries with weak social insurance structure.”
The 225-page report contains 111 charts that add visual analysis in order to explain the developing trends within the Global Interventional Cardiology Market. Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments of this market: Percutaneous Coronary Intervention (PCI), Transcatheter Aortic Valve Implantation (TAVI), Transcatheter Mitral Valve Implantation (TMVR). The PCI submarket is further segmented into Drug-eluting Stents (DES), Bare Metal Stents, and Bioresorbable Stents

The 225-page report offers market forecasts for the US, Germany, France, Italy, Spain, the UK, Japan, Australia, Singapore, China, India and the Rest of the World (RoW). Each country is further segmented into PCI, TAVI and TMVR.

In addition, the report contains a dedicated leading companies’ chapter covering the leading companies in this field.

The report Global Interventional Cardiology Market 2017-2027: Percutaneous Coronary Intervention (PCI), Transcatheter Aortic Valve Implantation (TAVI), Transcatheter Mitral Valve Implantation (TMVR) report will be of value to anyone who wants to better understand the interventional cardiology market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the interventional cardiology industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Rare Diseases Market Report 2021-2031

As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.

02 March 2021

Read

Visiongain Publishes Respiratory Inhalers Market Report 2021-2031

Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.

26 February 2021

Read

Visiongain Publishes Bile Duct Cancer Drugs Market Report to 2031

The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.

22 February 2021

Read

Visiongain Publishes Big Data Analytics in Healthcare Market Report to 2031

The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.

22 February 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever